NEW YORK (TheStreet) -- Valeant (VRX) has taken a beating in 2016 but the pharmaceutical company still has its believers, including famed value investor Bill Miller, who told CNBC at the "Delivering Alpha" conference Tuesday that he thinks the company could grow by 25% to 30% a year for the next five years.
That sort of growth expectation isn't entirely far-fetched, Guggenheim Securities Managing Director and Pharmaceutical Analyst Louise Chen said in a Wednesday afternoon appearance on CNBC's "Power Lunch."
"I think in the near-term, that kind of upside could even be conservative if Valeant is able to deliver upon some of the objectives that they have laid out for the company," Chen said. Chen believes that it's too early to look at Valeant's growth potential in terms of a five-year window. "I do think the street is missing a lot of the potential upside that the stock has here."
Valeant is considering selling off non-essential assets, company CEO Joseph Papa said at a conference organized by Morgan Stanley Tuesday.
However, the Laval, Quebec-based Valeant's growth will be driven more so by its ability to pay down debt and its products than by asset sales, Chen told CNBC.
"They have a great branded drug pipeline that they've been executing on and getting products approved and no one is giving them any credit here," she said.
Shares of Valeant were up slightly in afternoon trading Wednesday.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
We rate VALEANT PHARMACEUTICALS INTL as a Sell with a ratings score of D. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.
You can view the full analysis from the report here: VRX